

Article Type: Research Article

Received: 10/02/2022

Published: 13/04/2022



Open Access Journal of
Biogeneric Science and Research
ISSN 2692-1081

DOI: 10.46718/JBGSR.2022.11.000268

Serum Thyroid Hormones Pictures in Non-Thyroidal Illness Syndrome and Circulating Leptin Concentration in Patients With Uncontrolled Type 2 Diabetes Mellitus in a Group of Bangladeshi Population

Karim SA^{1*}, Samira J², Raihan SMR³, Bishawsh KB⁴, Faroque O⁵, Ali L⁶ and Mahtab H⁷

¹Sylhet MAG Osmani Medical College, Sylhet, Bangladesh

²Chittagong Medical College, Chittagong, Bangladesh

³University of North Carolina Greensboro (UNCG). USA

⁴Bio-Medical Research Group (BMRG), BIRDEM, Dhaka, Bangladesh

⁵Bio-Medical Research Group (BMRG), BIRDEM, Dhaka, Bangladesh

⁶Bio-Medical Research Group (BMRG), BIRDEM, Dhaka, Bangladesh

⁷BIRDEM Academy, Dhaka, Bangladesh

*Corresponding author: Sheikh Anwarul Karim, Sylhet MAG Osmani Medical College, APT: E5, ANZ Moonlight Candelia, 96 Panchlaish R/A, Road No: 02, Gate No: 08, Panchlaish, Chittagong, Bangladesh, Post Code: Chawkbazar-4203, Sylhet, Bangladesh

Abstract

Background: Thyroid diseases and diabetes mellitus are common endocrine disorders and Euthyroid Sick Syndrome is very common in uncontrolled type2 Diabetes Mellitus. As of thyroid hormones; the catabolic hormone Leptin is thought be closely linked with Diabetes Mellitus and Euthyroid Sick Syndrome.

Objective: To evaluate the thyroid hormone pictures in absence of clinical thyroid diseases among type2 diabetic subjects in a Bangladeshi population. To see the baseline serum leptin concentration in a group of Bangladeshi adult population and to document how the leptin is related to glycemic status and Sick Euthyroid syndrome in the setting of uncontrolled type 2 Diabetes Mellitus.

Method: This case and control study was carried out in the Endocrinology Department in collaboration with the Bio-Medical Research Group (BMRG), Research Division, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrinology and Metabolism (BIRDEM)), Dhaka, Bangladesh during the period of January 2000 to December 2002. A total of 100 type 2 diabetic subjects, 30-50 years of age, irrespective of glycemic status, duration of diabetes, Body Mass Index (BMI) and sex were recruited from the outpatient department (OPD) of BIRDEM hospital. Control subjects (n=30) were selected from friends and family of the patients within 5 years of age band without diabetes or impaired glucose regulation {Impaired Fasting Glycemia (IFG), Impaired Glucose Tolerance (IGT)} determined according to American Diabetic Association (ADA) criteria³⁷ and having no clinical thyroid diseases or other evident systemic diseases documented on clinical evaluation.

Results: It was observed that mean± SD of the thyroid hormone pictures in diabetic and control subjects were; TT3 (ngm/dl) {in controls (88.91±15.88) and in diabetic subjects (84.27±22.29)} was not statistically significant to each other (p=0.209). Mean±SD of TT4 (µgm/ dl) in control subjects was 8.32±1.64 and in the diabetic subjects was 9.26±1.44, which is almost similar in both the groups (p= 0.589). FT4: (pgm/ml) in control subjects was 2.60±0.54 and in diabetics was 2.53±1.72 (p= 0.830). FT4. (µgm/ dl) in control subjects was 1.43±0.22 and in diabetics subjects 1.36±0.25. (p 0.179). TSH (µlu/ml) in control subjects was 1.34±1.00 and in diabetic subjects 1.54±1.21 (p: 0.411). FT3; FT4 and TSH showed no significant difference between control and diabetic subjects. Thyroid hormones (TT3, TT4, FT3, FT4) and TSH were

reanalyzed according to HbA1c and BMI category and showed no significant differences. But when the FPG and HbA1c goes beyond 12 mmol/l and 10% respectively there was more worsening thyroid hormone pictures in comparison to groups whose FPG and HbA1c were below 12mmol/l and 10%. It was also noticed that there was a tendency to develop more lower thyroid hormone pictures and more deteriorating glycemic status in patient with low and normal BMI groups in comparison to higher BMI groups of patients. Insulin and leptin were found to have strong positive correlation with BMI and other indices of obesity. Serum leptin was also found to be positively correlated with FPG and HbA1c upto a certain limit, but HbA1c went beyond 10%; serum leptin concentration tended to be declined. Serum leptin and Insulin showed strong positive correlation to each other's. Thyroid hormones and TSH were re-analyzed and its relationship to FPG, HbA1c, fasting serum Insulin and Leptin were explored. Fasting serum Insulin and Leptin showed no significant differences among the different thyroid hormones groups.

Conclusion: Uncontrolled type2 diabetes mellitus is associated with alteration of thyroid hormone pictures particularly affecting TT3, FT3 and TSH. This biochemical feature is more evident if the BMI of the Diabetic subjects is low or within the normal range and also the more worsening the glycemic status, there was more deteriorating serum thyroid hormone pictures. Serum leptin was not found to have any relation with these changes.

Keywords: Leptin, Euthyroid Sick Syndrome (ESS), Diabetes mellitus, Body mass index (BMI)

Introduction

Diabetes Mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defect in insulin secretion, insulin action or both associated with hyperglycemia and disturbances in carbohydrate, lipid and protein metabolism. The chronic hyperglycemia of Diabetes is associated with long term damages, dysfunction and failures of various organs specially the heart, blood vessels, kidneys, eyes and nerves [1,2]. Thyroid diseases and diabetes mellitus are the two most common endocrine disorders [3]. Diabetic patients have increased prevalence of thyroid disorder, with hypothyroidism being the most common [4]. In diabetic patients, thyroid dysfunction varies from 2.2% -17%. Diabetic women are more commonly affected by thyroid dysfunctions than men [5]. Hypothyroidism occurs from a deficiency of thyroid hormones is a very common thyroid problem in diabetic patients [6]. Thyroid hormones and insulin are the antagonistic, and involved in the metabolism of carbohydrates, proteins, and lipids. Thyroid hormone as well as insulin are altered if there is functional impairment of the thyroid gland and endocrine pancreatic beta cells [7]. Diabetes Mellitus appears to influence thyroid function in two sites; firstly, at the level of hypothalamic control of TSH release and secondly at the conversion of T4 to T3 in the peripheral tissue. Increased hyperglycemia causes reversible reduction of the activity and hepatic concentration of T4-5'-deiodinase, low serum T3, increase in reverse T3 and also variation in the level of T4 [8].

Leptin the product of ob gene secreted by mature adipocytes from white adipose tissues and is supposed to transmit a satiety signal into the central nervous system. It is a hormone involved with body weight homeostasis by reduction in food intake and increase in energy expenditure. It was observed that plasma leptin levels is strongly correlated with BMI and other indices of adiposity

like Waist Hip (W/H) ratio, percent body fat and total fat mass and also the fasting Insulin levels in both Rodents and human [9-13]. Obese state is associated with dyslipidemia, hyperinsulinemia, insulin resistance and glucose intolerance with considerable morbidities and mortalities [14-16]. The risk of development of type2 Diabetes becomes greater with increasing obesity and insulin resistance. So that increasing adipose tissue mass could lead to insulin resistance, hyperinsulinemia, hyperleptinemia and Diabetes Mellitus [9,17-21].

Euthyroid Sick syndrome (ESS) or Non-thyroidal illness Syndrome (NTIS) identifies abnormalities of thyroid function tests observed in patients with systemic non-thyroidal illnesses and in those patients undergoing surgery or fasting [22-24]. Abnormalities of thyroid function tests observed in ESS or NTIS includes 1) Low T3 Syndrome 2) Low T3 and T4 syndrome 3) High TT4 syndrome 4) other abnormalities like low TT3 and TSH, high TSH and low TT3 and TT4 [25].

Thyroid hormones are also among the major regulatory hormones in maintenance of energy expenditure, adipose tissue masses and appetite raise the question of an interaction between leptin and thyroid hormones. Leptin was studied among ESS or NTIS patients in the setting of acute severe sepsis, Diabetic ketoacidosis, critically ill hospitalized patients and in patients with intensive care setting with controversial results [17-21]. Leptin and thyroid hormones have the property of common metabolic effects in maintaining body weight homeostasis by regulating eating behavior and energy expenditure [26-36]. Pathogenesis of type 2 diabetes involves predominantly insulin resistance with compensatory hyperinsulinemia which is truer in case of obese individuals [37] and these types of patients were found hyperleptinemic in many studies done until recently in abroad. So that it's an opportunity to document the interaction of leptin and thyroid hormones in modulating

the synthesis and secretion of each other in patients with uncontrolled type2 diabetes mellitus.

Experiments on both animal and human models Diabetes Mellitus was found to be associated with alteration of thyroid hormone picture in absence of clinical thyroid diseases irrespective of the type of diabetes. In both type1and type2 diabetes significant reduction of bothTT3 and FT3, increased rT3 and high rT3/T3 ratio was demonstrated [26-29]. Serum FT4 and FT4I were normal, TT4 was normal or suppressed and TSH was found normal or slightly elevated [30,31]. All the parameters of thyroid function specially TT3, FT3 and rT3 become normal when Euglycemia was achieved [27,32,33]. Moreover it was found that reduction of FT3 and TT3 , rise of rT3 are significantly correlated with the severity of hyperglycemia and the thyroid secretory response to large dose of TSH is also declined in uncontrolled diabetes mellitus which frequently improves with improved glycemic control [34].

A previous study among young Bangladeshi diabetic population demonstrated significant alteration of thyroid hormone pictures in absence of clinical thyroid diseases which is consistent with the other study done in abroad earlier [35]. But ESS or NTIS in the setting of type2 diabetes was not investigated extensively earlier and there is no available data regarding the changes in thyroid hormone pictures in patients with uncontrolled type2 Diabetes Mellitus among Bangladeshi population. Although there are few studies in abroad; which revealed that that there is significant alteration of thyroid hormones in uncontrolled type2 diabetic subjects [32,33,36,37]. As most of these studies did not exclude other causes of ESS or NTIS which are responsible for activating inner ring de-iodination or inhibition of outer ring de-iodination of T4 to produce T3 from T4 instead of rT3 [38] the result was found to be poorly representative.

In the above context our present study was designed to document the changes of thyroid hormones pictures in absence of clinical thyroid diseases among Bangladeshi population in the setting of uncontrolled type2 diabetes mellitus. As Leptin was previously not measured in Bangladeshi Population and its interaction with glycemic status, insulin and thyroid hormones in our population was completely unknown. So, our present study was also aimed to document the basal serum leptin and its relation to glycemic status and thyroid hormones in the study population.

Objectives and Methods

1) To evaluate the circulating thyroid hormone pictures in absence of clinical thyroid diseases among type2 diabetic subjects in a group of Bangladeshi population.

2) To measure the baseline serum Leptin concentration and to document whether it is related to glycemic status, serum insulin and thyroid hormones in the setting of uncontrolled type2 diabetes mellitus

3) To documents the relationship of serum Leptin with BMI and other anthropometric indices of obesity irrespective of glycemic status in a group of population in Bangladesh.

Methodology

Types of study:

This was a case and control study.

Place and duration of study

The study was conducted in the Endocrinology department in collaboration with the Bio-Medical Research Group (BMRG), Research Division, BIRDEM, Dhaka, Bangladesh during the period of January 2000 to December 2002.

Study population

A total of 100 type 2 diabetic subjects, 30-50 years of age, irrespective of glycemic status, duration of diabetes, BMI and sex were recruited from the outpatient department (OPD) of BIRDEM hospital. Prior to recruitment, diabetes mellitus was confirmed according to current American Diabetic Association (ADA) criteria for the diagnosis and classification of diabetes mellitus [37]. Control subjects (n=30) were selected from friends and family of the patients within 5 years of age band without diabetes or impaired glucose regulation (IFG, IGT) determined according to ADA criteria [37] and having no clinical thyroid diseases or other evident systemic diseases documented on clinical evaluation. Informed written consent was taken from all recruited diabetic and control subjects for the purpose of the study.

Exclusion criteria

- Type 2 diabetes with acute metabolic de-compensation.
- Type 2 diabetes with clinically detectable thyroid diseases.
- Type 2 Diabetes with clinically diagnosed other acute or chronic systemic diseases.
- Diabetic subjects with overt nephropathy in which serum creatinine > 2mg/dl
- Pregnancy and postmenopausal woman.

Method

Selection criteria as per availability and was given an

appointment to come in a particular date. Preparation of the subjects and collection of blood of the Controls and diabetic subjects that were assigned for the purpose of study done according to. 24 They were requested to fast overnight for at least eight hours and in the subsequent morning 16 ml of venous blood was drawn from the ante-cubital vein by using 25 cc disposable plastic syringe with 18G needle for the estimation of fasting serum leptin, insulin, C-peptide, glucose, HbA1c, TT3, TT4, FT3, FT4 and TSH. One ml of collected venous blood was taken in an anticoagulant containing vial for estimation of HbA1c. Remaining 15ml of blood was kept in 3 separate plain test tubes in equal amounts (5ml in each) to centrifuge immediately. Blood sample contained in the test tube was centrifuged for 15 minutes at a rate of 4000 rpm. A total of 200 μ l of serum was collected in appropriately labeled Eppendorf in duplicate with the help of micropipette for each of the biochemical parameters. Then the serum sample was preserved immediately at -30° C for analysis. FPG was measured by glucose oxidase method and HbA1c was measured by HPLC based analyzer, Leptin was measured by ELISA method, Insulin, c-peptide, TT3, TT4, FT3, FT4 and TSH was measured by Chemiluminescence technique in Immulite Auto-analyzer.

History and clinical examination

Detailed socio-demographic and clinical data were recorded in a pre-designed case record form. These include age, sex, residing area, occupation, socioeconomic status, dietary habit, exercise, alcohol and smoking habit, duration of diabetes, associated diseases like hypertension, obesity, dyslipidemia, coronary artery disease, cerebrovascular diseases, peripheral vascular diseases and crystal deposition diseases. Family history of these diseases were also been noted. Classical and non-classical features of diabetes mellitus and any adverse outcome of diabetes on life style was noted by taking history from the diabetic subjects.

Height, weight, BMI, waist circumference, hip circumference, waist hip ratio (WHR), waist height ratio (WHtR) of all the controls and diabetic subjects were recorded. Percent body fat and total fat mass was measured by "Body logic Body fat monitor; Omron Corporation, Japan." Biceps, Triceps, Subscapular and Suprailiac skin fold thickness (SFT) was measured by using appropriate tools. Systolic and diastolic blood pressure of all patients and control subjects was recorded. Blood pressure was measured by using mercury sphygmomanometer after at least 5 minutes of recumbence in a calm and quiet environment. Systolic blood pressure 130 mm Hg and the diastolic blood pressure 85 mm Hg was taken as the cut-off value for categorizing the normal and the abnormal values

among diabetic population 38. Diabetic neuropathy was tested by appropriate clinical test. Autonomic function test was done by documenting the heart rate variability and blood pressure response on standing. Motor neuropathy was tested by eliciting jerks and reflexes by the percussion hammer. Retinopathy of all diabetic subjects was screened by routine dilated fundoscopy in the BIRDEM ophthalmology outpatient department.

Statistical Analysis

All the data were expressed as mean \pm standard deviation, median (range) and/or number and percentage (%) as appropriate. Statistical analysis was done by using SPSS 7.5 packages for windows. Appropriate statistical test of significance like unpaired t test, one way analysis of variance (ANOVA) and Mann-Whitney test was used as necessary. $P < 0.05$ was taken as minimum level of significance.

Data presentation

Tabulation and / or drawing either in the form of graph or in the form of diagram were utilized as necessary for data presentation.

Results

Shown in Tables &, Figures.

Discussion

Some studies done earlier in abroad; the mean age (mean \pm SD) in years of type 2 diabetic patients who were participated in study was (47.5 \pm 7.4) coincides with the fact that type 2 diabetes mellitus usually develops after the age 40 years.^{9,26,27} Whereas in our study the mean age (mean \pm SD) of the control and diabetic subjects were 39.5 \pm 5.2 and 39.2 \pm 5.8 respectively. Serum leptin was measured in this study for the first time among the Bangladeshi population. So that the present study attempted to document the baseline serum leptin concentration among healthy population, variation of serum leptin in different glycemic status and BMI groups among type2 diabetic subjects. This study was also aimed to find out the sexual variation of serum leptin irrespective of glycemic status and its relation to thyroid hormones among uncontrolled type2 diabetic subjects [39-54].

The baseline serum leptin concentration among our healthy adult population (Tables 6-8) doesn't seem to differ from values documented for many diverse groups of populations [55] where they have found that median (range) of serum leptin levels in healthy male subjects having BMI 21-25 was 1.1 (0.5-3.3) and in female subjects in the same BMI groups was 3.2 (1.1-8.5). Serum leptin levels in male subjects having BMI 26-30 was 1.8 (0.8-4.9) and in their female counterpart was 5.6 (1.8-11.1) and BMI with 31-35

Table 1: Demographic status of the study group.

Groups	Age mean \pm SD	Annual Income Median (Range)	Family Member	SBP mean \pm SD	DBP mean \pm SD	Duration of DM, years
Controls (n=30)100	39.53 \pm 5.24	120000 (30000-220000)	6 \pm 1	120 \pm 23	80 \pm 7	--
DM (n=100)	39.24 \pm 5.79	100000 (20000-200000)	6 \pm 2	124 \pm 17	80 \pm 10	0.02 (0.01- 6)
t/p value		u/p value	t/p value			
Cont vs DM	-.248/0.804	1114/0.32*	1.1770/.241	1.177/0.241	1.101/0.273	--

In table 1 shows demographic status of the study group where mean \pm SD age of the control and diabetic subjects were 39.5 \pm 5.2 and 39.2 \pm 5.8 respectively. Duration of diabetes is one month to six years. Systolic and diastolic blood pressure of the control and diabetic subjects were almost similar and it was within normal range. The table given below showed it in detail:

Table 2: Clinical status of the study group.

Clinical history		Controls		Type-2 Diabetes mellitus	
		Number	Percentage	Number	Percentage
Sex	Male	16	53	52	52
	female	14	47	48	48
Type of work	Sedentary	27	90	84	84
	Physical work	3	10	16	16
Exercise	Regular	11	37	23	23
	Irregular	19	63	57	57
	No Exercise	0	0	20	20
Smoking	Smoker	2	7	20	20
	Non-Smoker	27	90	70	70
	Past Smoker	1	3	10	10
FH diabetes	Present	16	53	65	65
	Absent	14	47	23	23
FH HTN	Present	15	50	48	48
	Absent	15	50	36	36
FH obesity	Present	14	44	46	46
	Absent	16	56	54	54
FH CAD	Present	8	27	24	24
	Absent	22	73	52	52
FH CVD	Present	7	24	27	27
	Absent	23	76	50	50
H/O CAD	Present	1	4	38	38
H/O CVD	Present	0	0	06	6
Retinopathy	Present	0	0	35	35
Neuropathy	Present	0	0	35	35
Nephropathy	Present	0	0	25	25
Anti DM drugs	Present	0	0	24	24
Typical Symptoms	Present	0	0	37	37
Atypical Symptoms	Present	0	0	63	63

In table 2 shows clinical status of the study group where 53 out of 100 controls and 65 out of 100 diabetics have family history of diabetes. Family history of hypertension was found in 50 out of 100 and 48 out of 100 controls and diabetic subjects respectively. Family history of obesity was found in 44% controls and 46% diabetic subjects. Around 27% of controls and 24% of diabetic subjects have family history of coronary artery diseases (CAD) and 24% of control and 27% of diabetic patients have family history of cerebrovascular

Citation: Karim SA^{1*}, Samira J², Raihan SMR³, Bishawsh KB⁴, Faroque O⁵, Ali L⁶ and Mahtab H⁷. Serum Thyroid Hormones Pictures in Non-Thyroidal Illness Syndrome and Circulating Leptin Concentration in Patients With Uncontrolled Type 2 Diabetes Mellitus in a Group of Bangladeshi Population. Op Acc J Bio Sci & Res 11(3),2022

DOI: 10.46718/JBGSR.2022.11.000268

diseases (CVD). Early retinopathy and neuropathy were observed in 45.5% and 36.5% diabetic subjects. Nephropathy was documented in 25 diabetic subjects.

Table 3: Anthropometric Characteristic of the Diabetic and control subjects.

Parameters	Control group			Diabetic group			P value			*t/p value
	**MC	**FC	**TC	**MD	**FD	**TD	MC vs MD	FC vs FD	MD vs FD	TC vs TD
BMI	24.42± 3.16	26.11± 2.85	25.2± 3.09	24.41± 2.85	26.33± 3.77	25.3± 3.43	1.00	1.00	0.023	0.172/ 0.864
Waist Circumference	88.13± 6.35	87.29± 8.83	87.73± 9.19	90.06± 7.72	94.81± 10.49	92.34± 9.42	1.00	0.035	0.049	2.455/ 0.015
Hip Circumference	90.94± 5.79	90.86± 7.27	93.7± 7.08	91.77± 7.20	95.40± 9.13	93.51± 8.35	1.00	1.00	0.135	-0.113/ 0.91
W/H Ratio	0.97± 0.04	0.90± 0.09	0.94± 0.08	0.98± 0.07	0.99± 0.06	0.99± 0.07	1.00	0.001	1.00	3.14/ 0.002
W/Ht Ratio	0.53± 0.03	0.56± 0.06	0.54± 0.05	0.55± 0.04	0.61± 0.06	0.58± 0.07	100	0.009	0.000	2.57/ 0.011
% Body fat	25.55± 5.05	33.77± 5.96	29.39± 6.82	24.65± 5.09	32.26± 6.51	28.38± 6.95	100	100	0.000	0.72/ 0.74
Total Fat Mass	16.79± 5.71	22.03± 6.19	19.24± 6.40	16.49± 5.0	21.45± 6.10	18.87± 6.06	1.000	1.00	0.000	-0.29/ 0.77
Biceps SFT	8.73± 3.45	13.14± 2.98	10.78± 3.90	8.54± 2.61	11.81± 3.12	10.12± 3.09	1.00	0.866	0.000	-0.93/ 0.35
Triceps SFT	12.13± 2.59	16.41± 4.95	14.18± 6.04	11.93± 3.03	17.85± 5.16	14.7± 5.12	1.00	1.00	0.000	-0.79/ 0.44
Suprailiac SFT	21.51± 6.35	27.07± 5.32	24.10± 6.4	21.96± 6.19	28.76± 6.77	25.23± 7.29	1.00	1.000	0.0000	0.76/ 0.45
Subscapular SFT	24.07± 7.05	26.69± 6.81	24.10± 6.44	22.57± 6.02	28.18± 5.82	25.62± 4.16	1.00	1.000	0.013	0.58/ 0.56

**(MC=Male control, FC= Female Control, TC= Total Control, MD=Male Diabetic, FD= Female Diabetic, TD=Total Diabetic)

Results are expressed as mean±SD, p value was calculated using Anova Bonferrony. *t/p value was calculated using unpaired 't' test

Table 3: shows that FC and FD have significantly higher BMI than the MC and MD (p=0.05). FD also showed higher BMI than the MD at p=0.023 level. FD has significantly higher waist circumference than FC (p=0.035) and MD (p=0.049). TD have higher waist circumference than TC (t/p=2.455/0.015). FD have higher hip circumference than MD (p=0.135). MC have higher W/H ratio than FC, FD have higher W/H ratio than FC, TD also have higher W/H ratio than TC which are significant at p=0.05 levels. FC, FD and TD have significantly higher W/Ht ratio than MC, MD and TC respectively at p=0.05 levels. FC and FD have significantly higher % body fat and total fat mass than the MC and MD at p= 0.05 levels. Similar observation was also found in case of Biceps, Triceps, Suprailiac and Subscapular SFT.

have serum leptin levels 3.2 (1.2-8.2) and 8.8 (2.2-18.6) in male and female respectively.

Serum leptin levels was found to be positively correlated with BMI in both controls and diabetic subjects and in diabetic subjects it has shown strong positive correlation at p=0.0001 levels (Figures 5,9). Female subjects have shown significantly higher values (3-4 times) than their male counterparts irrespective of BMI and glycemic status (table-6). Similar degrees of hyperleptinemia were also found in in male and female subjects when they were categorized according to BMI (Table 8). This finding is similar

to the findings of the other studies done in abroad 21. Whwn serum leptin levels were reevaluated on the basis of BMI; leptin levels were found to be increased significantly with increasing BMI (p=value BMI A vs B=0.0001, A vs C=0.0001, B vs C=0.024) (Figures 6,7,8). Similar type of response was also found in control subjects though it was not statistically significant at p=0.05 levels (Figure 9). Percent body fat, total fat mass and other indices of obesity were also found to have strong positive correlation to serum leptin similarly to BMI at p=0.05 levels in both Diabetic and control subjects (Figures 11,12,13,17) which was found to be more obvious

Table 4: Thyroid hormone status in diabetic and control subjects.

Parameters	Control			DM			P value			*t/p value
	MC**	FC**	TC**	MD**	FD**	TD**	MCvs MD	FC vs FD	MD vs FD	TC vs TD
TT ₃	93.67± 17.14	83.46 ±12.78	88.91 ±15.88	85.02 ±22.7	83.46 ±22.0	84.27 ±22.3	0.912	1.00	1.00	-1.268 /0.209
TT ₄	8.54± 1.9	8.07± 1.31	8.32 ±1.64	8.22 ±1.90	8.63 ±1.69	9.26 ±9.44	1.00	1.00	1.00	0.54/ 0.589
FT ₃	2.69 ±0.36	2.56 ±0.55	2.60 ±0.54	2.40 ±0.68	2.37 ±0.74	2.53 ±1.72	0.816	1.00	1.00	0.215/ 0.83
FT ₄	1.49 ±0.21	1.37 ±0.23	1.43± 0.22	1.43 ±0.18	1.31 ±0.27	1.36 ±0.25	1.00	1.00	0.065	-1.35/ 0.179
TSH	1.33 ± 0.88	1.35 ±1.16	1.34 ±1.00	1.26 ±0.89	1.84 ±1.42	1.54 ±1.21	1.00	0.961	0.08	0.824/ 0.411

**(MC=Male control, FC= Female Control, TC= Total Control, MD=Male Diabetic, FD= Female Diabetic, TD=Total Diabetic).

In table 4 shows thyroid hormone status in diabetic and control subjects. Mean±SD of TT₃; (ngm/dl) in controls (88.91±15.88) and in diabetic subjects (84.27±22.29) was not statistically significant to each other (p=0.209). Mean±SD of TT₄ (µgm/dl) in control subjects was 8.32±1.64 and in the diabetic subjects was 9.26±1.44, which is almost similar in both groups (p= 0.589). FT₃ (pgm/ml) in control subjects was 2.60±0.54 and in diabetics was 2.534±1.72 (p= 0.830). FT₄ (ngm dl) in control subjects was 1.43±0.22 and in diabetics subjects 1.36±0.25. (p 0.179). TSH (µlu/ml) in control subjects was 1.34±1.00 and in diabetic subjects 1.54±1.21. (p: 0.411). FT₃; FT₄ and TSH showed no significant difference between control and diabetic subjects.

Table 5: Mean serum level of TT3, FT3 and TSH in patients with low levels of hormones and also in patients with normal values of hormones.

Groups	TT3	FT3	TSH
Groups with Low level of Thyroid hormone	58.46±12.32	1.31±0.44	0.50±0.49
Groups with Normal level of Thyroid hormone	93.81±16.91	2.53±0.59	1.50±0.86
T/p value	-11.45/0.0001	-6.83/0.0001	-6.018/0.0001

(Results are expressed as mean±SD, p value was calculated using ANOVA Bonferrony, t/p value was calculated using unpaired 't' test).

Table 5 showed that the mean serum TT3 in patients with low T3 syndrome groups of patients and in patients with normal values of TT3 were 58.46±12.32 and 93.81±16.91 respectively which was statistically significant (p=0.0001) between the two groups. Mean Serum TSH level in low TSH group was 0.47±0.395 and in normal TSH group was 1.50±0.86 which was statistically different significantly (p=0.0001) from each other. Serum FT3 levels in low FT3 groups and normal FT3 groups of patients were 1.31±0.44 and 2.53±0.59 respectively which was statistically different between the two groups.

Table 6: FPG, HbA1c, baseline Serum Leptin, Insulin and C-peptide level among diabetic and control subjects.

Parameters	Controls			DM			U/p value			
	**MC	**FC	**TC	**MD	**FD	**TD	MC vs MD	FC vs FD	TC vs TD	MD vs FD
**Leptin	1.29 (0.05-2.49)	4.03 (0.05-8.66)	1.65 (0.05-8.66)	0.71 (.11-2.420)	2.74 (.25-13.28)	1.21 (0.11-13.3)	278/ 0.046	241/ 0.110	1206/ 0.10	296.5 /0.000
**Insulin	7.25 (4.0-17.8)	8.15 (4.0-15.4)	8.05 (4.0-17.8)	6.35 (1.90-31.11)	8.4 (2.3-48.9)	7.8 (1.9-48.9)	356.5/ 0.39	327.5/ 0.886	1397.5/ 0.56	1001.5/ 0.089
**C-peptide	0.60 (.05-1.97)	0.45 (0.28-1.03)	0.48 (0.05-1.97)	0.79 (0.62-2.7)	0.80 (0.11-5.11)	0.75 (0.06-5.11)	394/ 0.756	127/ 0.000	1102/ 0.028	996/ 0.082
FPG	5.54± 0.75	5.72± 0.74	5.63± 0.74	10.97± 5.17	10.71± 4.05	10.85± 4.67	0.000	0.001	10.78/ 0.000	1.00
HbA1c	6.07± 0.67	6.13± 0.64	6.10± 0.64	10.22± 2.63	9.13± 2.21	9.7± 2.49	0.000	0.000	13.07/ 0/000	0.08

**{MC=Male control, FC= Female Control, TC= Total Control, MD=Male Diabetic, FD= Female Diabetic, TD=Total Diabetic}.

**Serum Leptin, insulin and C-peptide level were expressed as Median (Range).

FPG and HbA1c are expressed as mean±SD

In table 6 shows leptin, insulin, C-peptide, FPG and HbA1c level among diabetics and control subjects. Serum leptin levels in control subjects {1.65 (0.05-8.66)} was found lower their diabetic counterpart {1.21 (0.11-13.3)}, but it was not significant: (P=0.1000). But the leptin levels in male controls {1.29 (0.05-2.49)} was found significantly (P 0.000) lower than the female controls {4.03 (0.05-8.66)}. Similar observation was also noted in comparison between male diabetic {0.71 (0.11-2.42)}: and female diabetic subjects {2.74 (0.25-13.28)}; (p= 0.0001). FD have significantly higher serum Insulin and C-peptide levels than the MD (U/p=1001.5/0.089 and 996/0.082 respectively). FD have higher C-peptide levels than FC and MC, TD have higher C-peptide than the TC.

Table 7: Thyroid hormone pictures, glycemic status, serum insulin and leptin in diabetic subjects when categorized according to HbA1c.

Groups	TT ₃	TT ₄	FT ₃	FT ₄	TSH	FPG	HbA1c	S Insulin	S C-Peptide	Serum Leptin
GroupA n=13	78.42± 24.50	8.77± 1.15	2.40 ±0.59	1.37± 0.25	1.37± 0.25	5.97± 1.8	6± 0.56	5.9 (3.5- 12.5)	0.88 (0.11-5.1)	2.26 (0.44- 6.8)
GroupB n=15	89.71± 24.33	8.00 ± 1.53	2.35± 0.61	1.22± 0.27	1.90± 1.40	7.7± 1.9	7.37± 0.32	8.0 (3.2- 16.3)	0.71 (0.12-2.1)	3.08 (0.70- 7.9)
GroupC n=72	84.19 ±21.51	8.45 ±1.95	2.35± 0.73	1.39± 0.24	1.41± 1.11	12.39±4.5	10.84±1.89	7.9 (19- 48.9)	0.74 (0.06-3.6)	0.98 (0.11- 13)
P value								U/p value		
A vs B	0.554	0.773	0.255	0.774	0.135	0.749	0.09	75/ 0.30	88.5/ 0.67	79/0.39
A vs C	1.000	1.000	1.000	1.000	1.000	0.000	0.000	343/ 0.13	392/ 0.35	291.5/ 0.03
B vs C	1.000	1.000	1.000	0.97	0.862	0.000	0.000	513/ 0.76	469/ 0.42	253.5/ 0.001

(Group A=HbA1c < 7%, Group B=HbA1c 7%-8%, Group C=HbA1c > 8%)

(P value was calculated using one way analysis of variance, U/p value was calculated using Non-parametric Mann Whitney U test.)

In table 7 shows thyroid hormone pictures in diabetic subjects according to HbA1c. Thyroid hormones (TT3, TT4, FT3, FT4) and TSH were analyzed according to HbA1c category and showed no significant difference. Significant differences in serum leptin level were observed in different HbA1c groups. It was observed that the higher the HbA1c there was a tendency to be higher serum leptin concentration.


Table 8: Thyroid hormone pictures, Glycemic status, serum leptin and insulin among Diabetic subjects when categorized according to BMI.

Groups	Serum Leptin	Serum Insulin	Serum C peptide	FPG mg/dl	HbA1c%	TT ₃	TT ₄	FT ₃	FT ₄	TSH
BMI A N=55	0.80(0.11-0.83)	6.0(1.9-38.0)	0.74(0.06-3.62)	11.77±5.18	10.35±2.63	81.45±20.70	8.51±1.77	2.31±0.68	1.41±0.26	1.28±0.89
BMI B N=35	1.80(0.25-13.3)	8.6(2.3-48.9)	0.76(0.12-5.11)	9.66±3.79	8.83±2.01	89.54±24.58	8.46±1.78	3.02±2.72	1.32±0.26	1.78±1.51
BMI C N=10	4.5(1.26-7.3)	14.9(4.9-21.5)	0.94(0.20-2.13)	9.96±3.30	9.10±2.01	81.33±20.62	7.74±2.15	2.00±0.56	1.29±0.18	2.09±1.30
u/p value				P Value						
A Vs B	524/0.000	710/0.036	811/0.21	0.108	.013	0.285	1.000	0.164	0.721	0.160
A vs C	49/0.000	140/0.014	219/0.30	0.761	.399	1.000	1.000	1.000	0.651	1.000
B vs C	93/0.024	120/0.13	172/0.93	1.000	1.000	0.913	1.000	0.288	1.000	1.000

(BMI A=BMI upto 25). (BMI B=BMI 25.1-30). (BMI C=BMI>30)

(P value was calculated by ANOVA Bonferrony, U/p value was calculated using Mann-Whitney U test)

Table 8 showed that when TT3, TT4, FT3, FT4 and TSH were grouped according to BMI category and compared separately among control and Diabetic subjects in three BMI groups; no significant difference was observed. Significant differences of serum leptin and insulin was observed in different BMI groups. It was observed the higher the BMI, there were significantly higher serum leptin and insulin among the diabetic subjects.



In Figure 1 shows gender distribution of the study group where both the groups have shown in the figures in details. Male persons are 53/3% and females are 46.7% in controls and in type Diabetic group male patients are 52% and females are 48%.

Table 9: Glycemic Status, Fasting Serum Leptin and Insulin, indices of obesity in patients with low T3 syndrome and in patients with having normal T3 among the Diabetic subjects categorized according to BMI groups.

Groups		FPG	HbA1c	BMI	% body Fat	Total Fat Mass	Fasting Serum Insulin		Fasting S. Leptin	
BMI A	Low T ₃	14.24±7.13	10.74±3.15	23.16±1.39	23.46±5.45	7.6 (1.92-18.3)	7.6 (1.92-18.3)		0.76 (0.23-5.57)	
	Normal T ₃	10.18±3.61	10.18±2.39	22.74±1.89	25.48±5.84	5.55 (1.9-38.0)	5.55 (1.9-38.0)		0.82 (0.11-6.83)	
	t/p value	1.96/ 0.064	0.721/ 0.474	0.813/ 0.420	-1.210 /0.23	0.585/ 0.560	u/p value	*281/ 0.44	u/p value	0.813/0.420
BMI B	Low T ₃	9.55±4.40	9.08±2.41	27.19±1.25	33.31±4.83	8.0 (2.3-47)	8.0 (2.3-47)		3.9 (0.25-10.29)	
	Normal T ₃	9.70±3.68	8.76±1.93	27.33±1.45	3.72±5.82	8.8 (3.5-48.9)	8.8 (3.5-48.9)		1.66 (0.32-13.28)	
	t/p value	-0.094/ 0.925	0.380/ 0.706	-0.233/ 0.817	1.146/ 0.26	0.644/ 0.524	u/p value	*99/ 0.72	u/p value	78/ 0.24
BMI C	Low T ₃	10.45±0.64	9.55±1.34	33.41±3.61	36.85±6.29	13.4 (5.3-21.5)	13.4 (5.3-21.5)		4.27 (1.26-7.28)	
	Normal T ₃	9.84±3.73	8.99±2.54	31.63±1.60	37.30±4.10	14.9 (4.9-20.8)	14.9 (4.9-20.8)		4.5 (2.08-6.33)	
	t/p value	0.222/ 0.83	0.294/ 0.776	1.144/ 0.286	-1.182/ 0.901	0.335/ 0.726	u/p value	*7.0/0.79	u/p value	8.0/ 1.00

(BMI A=BMI upto 25). (BMI B=BMI 25.1-30). (BMI C=BMI>30). t/p value was calculated by using “student t test”. *U/p value was calculated by using Non-Parametric Mann Whitney test.

Table 9 showed that when diabetic patients with low T3 and Normal T3 were reanalyzed according to BMI category then it was found that low T3 subjects having normal BMI showed significantly higher serum fasting glucose (14.24±7.13) levels compared to the patients with normal T3 (10.66±3.61).but here no differences was observed in serum leptin and insulin and other indices of obesity in patients with normal T3 groups of subjects and in patients with low T3 syndrome.

in diabetic subjects. This finding is consistent with the findings of the other study [50].

When glycemic status was taken into consideration; serum leptin was found to have higher values among diabetic subjects than the matched control subjects. But it was found significant at p=0.05 levels only in comparison to MC vs MD and in MD vs FD it was found significant at p=0.0001 levels (Table 6).

Serum leptin concentration was again evaluated in relation to glycemic status categorized according to HbA1c. Leptin levels was found to be positively correlated with glycemic status up to a certain limit, that is the more the FPG

and HbA1c, there was more circulating leptin among the diabetic subjects. But when HbA1c goes beyond 10% serum leptin was found tended to be declined in comparison to other HbA1c groups (Figures 15 and Table 7). It suggests that most of the newly diagnosed type2 diabetic subjects were hyperleptinemic at least in the early stages of the diseases. As because due to the natural courses of the type2 diabetes mellitus these group of patients might be initially presented with biochemical features of insulin resistance particularly in those individuals with high BMI which is supported by others studies [47,48]. No significant differences of insulin were found in control and diabetic subjects; but when categorized according to BMI significant increment of

Table 10: Glycemic status, Fasting serum Leptin and Insulin, % body fat and total fat mass in different status of thyroid hormones.

Groups		FPG	HbA1c	Fasting S. Insulin	Fasting S. Leptin	BMI	%Body Fat	Total Fat Mass
TT ₃	Low TT ₃ (n=27)	12.57± 6.44	10.16± 2.89	7.7 (1.9-47.0)	1.05 (0.23- 10.29)	25.11± 3.35	27.37± 3.74	18.12± 5.93
	Normal TT ₃ (n=73)	10.21± 3.63	9.52± 2.32	8 (1.9-48.9)	1.22 (0.11- 13.28)	25.41± 3.45	28.72± 6.83	19.14± 6.13
	t/p value	2.30/ 0.024	1.572/ 0.119	972/ 0.92*	950/0.78*	-0.384/ 0.702	-0.856/ 0.394	-0.753/ 0.453
FT ₃	Low FT ₃ (n=12)	11.45± 5.09	9.98± 2.43	7.4 (4.4-38.0)	1.18 (0.39- 7.87)	26.59± 3.52	30.42± 7.24	21.42± 5.94
	Normal FT ₃ (n=88)	10.77± 4.61	9.66± 2.51	7.8 (1.9-48.9)	1.21 (0.11- 13.28)	25.16± 3.33	28.07± 6.91	18.52± 6.03
	t/p value	0.475/ 0.636	0.426/ 0.671	480.5/ 0.61*	480.5 /0.62*	1.357/ 0.178	1.096/ 0.276	1.562/ 0.122
TSH	Low TSH (n=12)	12.24± 4.16	10.86±2.48	8.3 (1.9-48.9)	1.57 (0.39- 2.68)	25.27± 1.82	30.19± 7.65	19.98± 5.0
	Normal TSH (n=88)	10.81± 4.78	9.65± 2.48	7.7 (1.96-47.0)	1.2 (0.11- 13.28)	25.21± 3.65	27.63± 6.66	18.40± 6.20
	t/p value	0.986/ 0.327	1.573/ 0.137	461.5/ 0.48*	488.5/ 0.48*	0.449/ 0.218	1.524/ 0.782	0.982/ 0.624

t/p value was calculated by using "student t test".

*U/p value was calculated by using Non-Parametric Mann Whitney test.

Table 10 showed the analysis of TT₃, FT₃ and TSH and its relationship to FPG, HbA1c, Fasting serum insulin, BMI and also with %body fat and total fat mass. 27 diabetic subjects have shown T₃ levels below the lower limit of normal range at FPG levels 12.57±6.44 and HbA1c 10.16±2.89. FPG value was significantly (p=0.024) higher in low T₃ group compared to normal TT₃ group. 12 diabetic subjects were found to have FT₃ below the lower limit of normal range at FPG level 11.45±5.09 and HbA1c level 9.98±2.43. Again 12 diabetic subject were found to have TSH below the lower limit of normal range at FPG level 12.24±4.16 and HbA1c level 10.86±2. Fasting serum leptin and insulin levels showed no significant differences among the different groups of TT₃, FT₃ and TSH. Similar observation was also noted in case of %body fat, total fat mass and in BMI.

serum insulin was observed with increasing BMI among the diabetic subjects (Figure10) which indicate that high BMI group of patients are associated with hyperinsulinemia and insulin resistance.

Serum leptin was assessed in relation to insulin and C-peptide. It was found that serum insulin and leptin were positively associated with each other's in both control and diabetic subjects (Figure 16). When the study subjects were divided into three BMI and HbA1c groups this relationship was maintained all through. This finding is consistent with the hyperleptinemic/ hyperinsulinemic or insulin resistant/ leptin resistant hypothesis in obese type2 diabetic subjects^{51,52}. This type of relation was also marked in case of leptin and C-peptide (Figure 14).

Thyroid hormones among control and Diabetic subjects were evaluated and it was found that the differences observed in serum thyroid hormones and TSH levels between controls and diabetic subjects were not statistically significant. When the thyroid hormones and TSH were reevaluated on the basis of BMI and HbA1c groups among the diabetic subjects, similar observation was noted (Table 6 and 7). But when serum TT₃, TT₄, FT₃, FT₄, and TSH values of all the diabetic subjects were divided into two groups by applying the cut off values to each hormone into normal values of thyroid hormones group and TSH with low values of thyroid hormones groups and TSH among the diabetic subjects, 27 diabetic patients were found to have low TT₃ below the lower limit of normal range than that of their normal counterpart which was significant at p=0.0001

level (Table-5 and 9), 12 patients were found to have serum FT3 levels which was significantly ($p=0.0001$) lower than their normal counterpart groups. Again 12 diabetic subjects were found to have low TSH level than their normal groups. 4 diabetic subjects were found to have significantly lower serum TT4 when compare to normal TT4 groups. When the TT3, FT3, TT4, and TSH groups were reanalyzed in relation to fasting serum glucose and HbA1c, low thyroid hormones and low TSH group have significantly ($p=0.0001$) higher fasting serum glucose and HbA1c than the groups with hormones within the normal range (table-9,10). The diabetic patients with Low TT3 showed strong negative correlation to FPG and HbA1c and no correlation in patients with normal TT3 (Figures 2 and 3). This finding is consistent with the findings of the other studies done in abroad in both type 1 and type 2 diabetic subjects 24-29, 41-44. Our findings showed that around the level of 12mmol/l of fasting serum glucose was associated with marked alteration of thyroid hormone picture in the blood in absence of clinical thyroid diseases. When low TT3 group was categorized according to BMI, diabetic subjects having BMI within normal range was found to have more deteriorating fasting serum glucose, HbA1c and serum TT3 levels; compare to other BMI groups (Table 9). This finding suggests that changes in thyroid hormone possibly much more obvious in young diabetic groups who are mostly have low or normal BMI than the type2 diabetic subjects that are mostly associated with obesity and higher degrees of BMI. These findings also supports the findings of the others study done in abroad [34] and also in the cell and molecular biology department of BIRDEM, Dhaka, Bangladesh [35]. Our findings also conclude that BMI and other indices of obesity possibly have very little or no impact on serum thyroid hormones and TSH levels until and unless they are associated with very high serum fasting glucose levels beyond 12mmol/l (Figures 2, 3).

Serum leptin levels was assessed separately among the diabetic subjects associated with significantly low serum TT3 levels. Serum leptin levels was found to be negatively correlated with low TT3 state among the diabetic subjects, though it was not significant at $p=0.05$ levels (Figure 4). As mentioned earlier a previous study documented the declining of serum leptin concentration among the clinically hypothyroid patients [53]. Our findings differ the findings of the SR Bornstein et al which documented the increment of serum leptin concentration in low TT3 Syndrome in the setting of acute severe infection 17. Raised serum leptin concentration in this study was possibly due to the effect of stress induced release of corticosteroid. As because it was found that hypercortisolimic state is associated with marked hyperleptinemic response⁵⁴. But our findings in ESS is consistent with the findings of Corsonello A et al [18] which

documented the declining of serum leptin concentration in elderly Sick Euthyroid Syndrome patients.

Conclusion

- i. Serum leptin concentration is almost similar to that of other population as reported earlier in European subjects. Also, there was a substantial sexual dimorphism in serum leptin levels with about 3 to 4 times higher values in female irrespective of obesity and diabetes.
- ii. Serum leptin was found to have strong positive correlation with BMI and other indices of obesity irrespective of glycemic status. It was also found that serum leptin and insulin is positively associated with each other.
- iii. Uncontrolled type 2 diabetes mellitus is associated with alteration of thyroid hormone pictures particularly altering the TT3, FT3 and TSH in absence of clinically evident thyroid diseases.
- iv. This biochemical feature of "Sick Euthyroid Syndrome" is more evident if the BMI of the subjects is low or normal range and it was also found that the more worsening the glycemic status as determined by FPG and HbA1c, there was more deteriorating circulating serum thyroid hormone pictures and TSH.
- v. Uncontrolled type2 diabetes mellitus was found to have associated with ESS or NTIS and serum leptin was found to have negative or no correlation with ESS or NTIS.

Acknowledgement and disclosure

I hereby acknowledge and express my honor and gratitude

To Professor Hajera Mahtab, the supervisor of the research work, for her guidance, advice and contribution for selection of the title of the research work, designing of the protocol and all through contribution to complete the work.

To Professor Liaquat Ali, co-supervisor of the research work for constant guidance, constructive criticism, developing scientific and research interest within me and also arranging the fund for completing the research work throughout the whole tenure of the work.

To Dr Samira Jamal for data collection, data entry and compiling the data, preparation of the manuscript and all through contribution for the work.

To Sheikh Raihan for data entry, data compilation, data analysis and manuscript preparation during the whole period of the work.

To Omar Faroque for giving all through support for

laboratory specimen collection, specimen preparation and preservation and finally laboratory analysis of all biochemical parameters throughout the whole period of the work

Kazol Baron Bishawsh for giving support for laboratory specimen collection, specimen preparation and preservation and finally laboratory analysis of all biochemical parameters throughout the whole period of the work.

Conflict of Interest

There was no conflict of interest with any person, organization, groups, companies, diagnostic laboratories or any other financial institutions in conducting the research works.

Ethical Declaration

This research work was duly approved by the Institutional Ethical Committee of the BIRDEM Academy, Dhaka, Bangladesh

References:

1. Tiwari AK, Roa JM (2002) Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospectus. *Current Science* 83(1): 30-38.
2. Sreelatha M, Kumar VS, Shekar GC, Shekar VC (2017) Study of Thyroid Profile in Patients with Type 2 Diabetes Mellitus. *International Journal of Scientific Study* 5(2): 211-220
3. Uppal V, Chittranjan V, Gurdeep KB, Anil V, Basu DB (2013) Thyroid Disorders in Patients of Type 2 Diabetes Mellitus. *Ind J ClinBiochem* 28(4): 336-341.
4. Wu P (2000) Thyroid disease and diabetes. *Clinical diabetes* 18(1): 1-10.
5. Srinidhi R, Ashok KJ, Prajna K, Shobith KS, Tirthal R, et al. (2013) Thyroid function in type 2 diabetes mellitus and diabetic nephropathy. *Journal of Clinical and Diagnostic Research* 7(8): 1583-1585.
6. Alok M, Pawan KK, Kamla PM, Raj KC (2016) Study of thyroid dysfunction in type 2 diabetes mellitus patients of Agra city. *International Journal of Biomedical Research* 7(01): 026-029.
7. Sugure, DD, McEvoy M, Drury MI (1999) Thyroid disease in diabetics. *Postgrad Med J* pp. 680-684.
8. Shah SN (1984) Thyroid disease in diabetes mellitus. *J Assoc Physicians India*. 32(12): 1057- 1059.
9. J Girard (1997) is leptin link between obesity and insulin resistance? *Diabetes and Metabolism* 23(3): 16-24.
10. MW Schwartz, RLPrigeon, SE Khan, M Necolson, J Moore, et al. (1997) Evidence that Plasma Leptinand insulin level are associated with body adiposity via different mechanism. *Diabetes care* 20(9): 1476-1481.
11. Jack SD, Fanelli C, Paramore D, Joy Brothers, Landt M (1996) plasma Leptin and Insulin relationship in obese and non-obese human. *Diabetes* 45(5): 695-698.
12. Kalaczynski JW, Nyce MR, Considine RV, Boden G, Nolan JJ, et al. (1999) Acute and Chronic effect of insulin on leptin production in humans, studies in vitro and in vivo. *Diabetes* 45(5): 699-701.
13. Widjaza A, Stratton JM, Horn R, Holman RR, Turner R, et al. (1997) UKPDS 20; Plasma leptin , obesity and plasma insulin in type2 Diabetes. *J Clin Endocrinol Metab* 82(2): 654-657.
14. Kaplan NM (1989) The delay quartet; upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. *Arch Intern Med* 149: 1514-1520.
15. Daly PA, Landsbergh I (1991) Hypertension in obesity and NIDDM: role of insulin and sympathetic nervous system. *Diabetes Care* 14: 240-248.
16. Stevens J, Caij, Pamuk ER, Williamson DF, Thun MJ, et al. (1998) The effect of age on the association between body mass index and mortality. *N Eng J Med* 338: 1-7.
17. Bornstein SR, Torpy DJ, Chrousos GP, Licinto I, Engelmann L (1997) Leptin Levels are elevated despite low thyroid hormones. *J Clin Endocrinol Metab* 82(12): 237-240.
18. Corsonello A, Buemi M, Artimisia A, Giorgianni G, Mauro VN, et al. (2000) Plasma leptin concentration in relation to Euthyroid Sick Syndrome in Elderly Patients with Non-thyroidal Illness. *Gerontologist* 46(2): 64-70.
19. Hathout EH, Sharkey J, Racine M, Ahn D, Mace JW, et al. (1999) Changes in plasma leptin during the treatment of diabetic ketoacidosis. *J Clin Endocrinol Metab* 84(12):4545-4548.
20. Saini JS, Naqvi S, Gandh B, Karnani I (1993) Thyroid hormones in diabetic ketoacidosis before and after therapy. *J Assoc Physicians India* 41(7): 415-417.
21. Nakamura S, Nagasaka S, Ishikawa K, Fujibayashi A, Kawakami (1999) Serum levels of leptin and it's changes during the course of recovery from diabetic ketoacidosis. *Diabetes Research and Clinical Practices* 46: 57-63.
22. Chopra IJ (1996) Euthyroid Sick Syndrome, abnormalities in circulating thyroid hormones and thyroid hormone physiology in non-thyroidal illness syndrome. *Med Grand Round* 1, pp. 201-202.
23. Chopra IJ (1996) Non thyroidal illness syndrome or Euthyroid Sick Syndrome. *Endocr Pract* 2: 45-52.
24. Wartofsky L, Burman KD (1982) Alteration in thyroid function in patients with systemic illnesses, the Euthyroid Sick Syndrome. *Endocr Review* 3:164-217.
25. Chopra IJ, Hershman JM, Pardridge WM, Neology JT (1983) Thyroid function in Non-thyroidal Illness. *Ann Intern Med* 1983; 98: 946-957.
26. Nunez AM, Sarmiento EG, Martin PE, Miguel CE, Pinilla JC, et al. (1990) Thyroid function study in patients with Diabetes Mellitus. *Ann Med Intern* 7(6): 291-293.
27. Kabadi UM (1986) Serum T3 and Reverse T3 concentration, indices of metabolic control in diabetes mellitus. *Diabetes Res* 3(8): 417-421.
28. Lu G (1993) Changes in circulating lymphocyte tri-iodothyronine receptor in diabetes mellitus. *Chung Hua I Chih Hsueh* 73(9): 517-519.
29. Radetti G, Paganine C, Gentli L, Banbin F, Pasquino B, et al. (1994) Altered adrenal and thyroid function in children with insulin dependent diabetes mellitus. *Acta Diabetol* 31(3): 138-140.
30. Castro N, Seafidi V, Borsellero T (1991) Changes in the thyroid hormone picture that may be found in severely decompensated type2 diabetics. *Menerva Med* 82(1-2): 9-14.
31. Steger RW, Rabe MB (1997) The effect of diabetes mellitus on endocrine and reproductive function. *Proc Soc Exp Biol Med* 214(1): 1-11.
32. Schnack C, Scherthner G (1986) pituitary-thyrotroph functions and thyroid hormones in long standing type2 diabetic before and after insulin treatment. *Exp Endocrinol* 90(2): 243-248.
33. Bagchi N, Palaniswami N, Desai H, Fellicetta J, Brown TR (1998) Decrease thyroid response to thyrotropin in type2 diabetes mellitus. *Metabolism* 37(7): 669-667.
34. Mollah FH (1996) Study of thyrometabolic state and autoimmune manifestation in MRDM. M Phil Thesis. IPGMR and BIRDEM:
35. Bhu N, Meena HS, Jailal J (1988) Thyroid in NIDDM. *J Assoc Physicians India* 36(12): 713-714.
36. Greenspan FS (1997) The Thyroid gland in: Basic and Clinical Endocrinology, FS Greenspan, GI Strewter, 5th edition, A Lange Medical Book pp. 216-217.
37. Report of the expert committee on the diagnosis and classification of Diabetes Mellitus. *Diabetes Care* (2000) 23(1): 4-9.
38. Chalmers J (1999) Who and International society of HTN guidelines for the management of Hypertension. *J Hypertens* 17:151-185.
39. Shekhar CY, Alwin S, Biswajit M (2012) Status of Thyroid Profile in Type-2 Diabetes Mellitus. *Journal of Nobel Medical College*. 1(2):64-71.
40. David, M, Ath MD (2012) Initial management of glycemia in type-2 diabetes mellitus" *NEJM* 347(17): 1342-1349.
41. Singh G, Gupta V, Sharma AK, Gupta N (2011) Frequency of thyroid dysfunction among diabetes in Punjabi population. *Adv. Biores* 2: 3- 9.
42. Kandasamy N, Rajendran T, Vallathol DH, Radhakrishnan V, Mani AB, et al. (2016) A Study on correlation between HbA1c levels with TSH levels in patients with Hypothyroidism and Type 2 Diabetes Mellitus. *J Evolution Med Dent Sci* 5(54): 3645-3652
43. Udiog CEJ, Udoh AE, Etukudoh ME (2007) Evaluation of Thyroid Function in Diabetes Mellitus in Calabar, Nigeria. *Indian Journal of*

Citation: Karim SA^{1*}, Samira J², Raihan SMR³, Bishawsh KB⁴, Faroque O⁵, Ali L⁶ and Mahtab H⁷. Serum Thyroid Hormones Pictures in Non-Thyroidal Illness Syndrome and Circulating Leptin Concentration in Patients With Uncontrolled Type 2 Diabetes Mellitus in a Group of Bangladeshi Population. *Op Acc J Bio Sci & Res* 11(3),2022

DOI: 10.46718/JBGSR.2022.11.000268

- Clinical Biochemistry. 22(2): 74-78.
44. Pasupathi P, Chandrashekar V, Senthil Kumar U (2009) Evaluation of oxidative stress, antioxidant and thyroid hormone status in patients with diabetes mellitus. *J Medicine* 10: 60-66.
45. Donckier JE (2003) Endocrine diseases and diabetes. In: Pickup JC, Williams G, editors. *Text book of diabetes mellitus*. Chichester: Blackwell pp. 271-2725
46. Schwartz RL Prigeon, SE Khan, M Necolson, L Moore, A Morawiecke, EJ Boyko, et al. (1997) Evidence that plasma leptin and insulin levels are associated with body adiposity via different mechanism. *Diabetes care* 20(9): 1476-1481.
47. Jirard J (1997) Is leptin link between obesity and insulin resistance? *Diabetes and Metabolism* 23(3): 6-24.
48. Groop LC (1999) Insulin resistance; the fundamental triggers of type 2 diabetes. *Diabetes Obesity Metabolism* 1(1): S1-S7.
49. Mc Garry (1995) Appetite control; does leptin lighten the problem of obesity? *Current biology* 93: 1342-1344.
50. Kristensen K, Pedersen SB, Langdahl LB, Richelsen B (1998) Regulation of leptin by thyroid hormones in humans, studies in vivo and in vitro. *Metabolism* 48(12): 1603-1607.
51. Mantzoros GS, Qu D, Friderich RC, Susulic VS, Lowell BB, Maratos Flier JS (1996) Activation of $\beta 3$ adrenergic receptor suppresses leptin expression and mediates a leptin independent inhibition of food intake in Mice. *Diabetes* 45: 909-914.
52. Chopra IJ (1996) Euthyroid sick syndrome, abnormalities in circulating thyroid hormones and thyroid hormone physiology in nonthyroidal illness syndrome. *Med Grand Round* 1: 201-212.
53. Valcavi R, zine M, Perio R, Casaueva FF, Dieguez C (1997) Influence of thyroid status in serum immunoreactive leptin levels. *J Clin Endocrinol Metab* 82(5): 16632-11634.
54. Malmstrom R, MR tas Taskinen, SI karonen, HY Jervinen (1996) Insulin increases plasma leptin concentration in normal subjects and in Patients with NIDDM. *Dibetologia* 1996; 39: 993-996.
55. Leptin Assay Manual (1998) DRG Leptin ELISA, August 20, p. 1-5.